Ex-Abbott reps sue for overtime pay

Share this article:
Two former Abbott Laboratories sales reps have sued the company in federal court in Chicago, claiming the drugmaker denied them overtime wages.

The lawsuit, which seeks class-action status, comes on the heels of lawsuits filed last year by reps against pharmaceutical companies including Astra-Zeneca, Eli Lilly, Johnson & Johnson and Pfizer.
The lawsuit argues that Abbott classifies its sales reps as exempt under the federal Fair Labor Standards Act, meaning they are not entitled to receive overtime pay.

Under current federal labor laws, sales forces can be exempt from overtime wages. But attorneys for the plaintiffs in the case argue that drug reps often work up to 70 hours a week and should not be classified as sales people.

“Although the companies claim that the representatives are salespersons and therefore not protected by overtime laws, with some exceptions, they actually don't sell anything,” said attorney Charles Joseph of Joseph & Herzfeld, who filed the lawsuit on behalf of the former Abbott employees. “Rather, they are tasked to influence the prescribing behaviors of doctors.”

The lawsuit is asking the court to order Abbott to start paying overtime to its pharmaceutical reps and seeks compensation to current and former employees denied overtime pay.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?